Sami-Sabinsa Group – parent company to nutraceutical health supplement and herbal extract supplier Sabinsa – inaugurated a new state-of-the-art manufacturing facility in the city of Hassan in southern India.
Pharmaceutical corporation Sabinsa completed a 90 day, multicentric randomised open label trial of its Amla, aka Indian gooseberry, extract and concluded it could provide blood sugar benefits.
Sabinsa has secured Novel Food approval for its patented curcuminoid metabolite ingredient C3 Reduct, giving supplement manufacturers in Europe a bioavailable curcuminoid option.
The European Food and Safety Authority (EFSA) concludes that the Novel Food tetrahydrocurcuminoids, derived from turmeric (C. longa L.), is safe for adult use in supplements at 140 milligrams per day (mg/day).
The supplementation of a formula containing seven herbal extracts has shown effects comparable to the blood sugar control drug metformin in prediabetic and newly diagnosed diabetic patients, according to a RCT by Sabinsa.
September 2021 and while the nights draw in and the temperature drops, opportunities in the food and nutrition sector remain red-hot as NutraIngredients features those seeking a new challenge.
The American Liver Foundation estimates at least 25% of the US population has nonalcoholic fatty liver disease, a condition in which excess fat is stored in your liver. NAFLD is the most common chronic liver condition and currently there are no approved...
Sabinsa Corporation is launching two novel water-soluble ingredients, one from of Boswellia serrata, called Polybos, and the other called MoringIn from Moringa oleifera.
Sabinsa has achieved self-certification for its Amla ingredient, Saberry, after an independent panel of scientifists took no issue with its safety and toxicology data.